Toll Free: 1-888-928-9744
Published: Mar, 2016 | Pages:
419 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Pfizer Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Pfizer Inc. - Product Pipeline Review - 2016', provides an overview of the Pfizer Inc.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Pfizer Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Pfizer Inc. - The report provides overview of Pfizer Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Pfizer Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Pfizer Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to buy - Evaluate Pfizer Inc.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Pfizer Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Pfizer Inc.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 7 Pfizer Inc. Snapshot 8 Pfizer Inc. Overview 8 Key Information 8 Key Facts 8 Pfizer Inc. - Research and Development Overview 9 Key Therapeutic Areas 9 Pfizer Inc. - Pipeline Review 21 Pipeline Products by Stage of Development 21 Pipeline Products - Monotherapy 22 Pipeline Products - Combination Treatment Modalities 23 Pipeline Products - Partnered Products 24 Pipeline Products - Out-Licensed Products 27 Pfizer Inc. - Pipeline Products Glance 31 Pfizer Inc. - Late Stage Pipeline Products 31 Pfizer Inc. - Clinical Stage Pipeline Products 35 Pfizer Inc. - Early Stage Pipeline Products 39 Pfizer Inc. - Drug Profiles 42 (naltrexone hydrochloride + oxycodone hydrochloride) ER 42 crizotinib 44 palbociclib 48 tofacitinib 52 epoetin zeta 56 gemtuzumab ozogamicin 58 tafamidis meglumine 59 (ertugliflozin + metformin hydrochloride) 61 (ertugliflozin + sitagliptin phosphate) 62 adalimumab biosimilar 63 axitinib 64 bevacizumab biosimilar 68 bococizumab 69 bosutinib 70 celecoxib 73 dacomitinib 75 ertugliflozin 78 gosogliptin 80 infliximab biosimilar 81 inotuzumab ozogamicin 82 meningococcal [serotype B] vaccine 84 pregabalin 86 pregabalin CR 88 rituximab biosimilar 89 rivipansel sodium 90 sildenafil citrate 93 sunitinib malate 95 tanezumab 99 trastuzumab biosimilar 102 ziprasidone mesylate 103 ascrinvacumab 104 Dekavil 105 domagrozumab 106 fosdagrocorat 107 gedatolisib 108 glasdegib 110 lorlatinib 112 Nimenrix 114 nirogacestat 117 PF-00489791 119 PF-00547659 120 PF-02545920 122 PF-04236921 124 PF-04457845 125 PF-05089771 126 PF-06290510 128 PF-06291874 130 PF-06425090 131 PF-06838435 132 ponezumab 133 temsirolimus 135 agatolimod sodium 137 pegfilgrastim 140 PF-06747775 141 filgrastim 142 HIV vaccine 143 PF-04136309 144 PF-04447943 146 PF-04518600 147 PF-04958242 148 PF-05082566 150 PF-05206388 152 PF-05230907 153 PF-05251749 154 PF-05402536 155 PF-06266047 156 PF-06273340 157 PF-06282999 158 PF-06293620 159 PF-06342674 160 PF-06412562 161 PF-06413367 162 PF-06427878 163 PF-06444752 164 PF-06444753 166 PF-06480605 167 PF-06647020 168 PF-06647263 169 PF-06648671 170 PF-06649751 171 PF-06650808 172 PF-06650833 173 PF-06651600 174 PF-06664178 175 PF-06669571 176 PF-06678552 177 PF-06700841 178 PF-06741086 179 PF-06751979 180 PF-06753512 181 PF-06755990 182 PF-06755992 183 PF-06801591 184 PF-06815345 185 Biologics for Undisclosed Indication 186 Biologics to Target PCSK-9 for Hypercholesterolemia 187 CE-355621 188 Drugs for Duchenne Muscular Dystrophy 189 GIBH-1008 190 GIBH-1010 191 GIBH-1018 192 GL-2045 193 HSD-621 194 J-17 195 Monoclonal Antibodies for Solid Tumor 196 MOR-8457 197 NIC7-DT 198 PD-0360324 199 PF-01247324 200 PF-06380101 201 PF-06447475 202 PF-06671008 203 PF-1355 204 PF-3845 205 PF-4989216 206 PF-5006739 207 PNU-120596 208 Proteins to Agonize MC4R for Obesity 209 RBT-301 210 Small Molecule 1 for Solid Tumors 211 Small Molecule to Antagonize Tie-2 Receptor for Solid Tumor 212 Small Molecule to Inhibit IDO-1 for Oncology 213 Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections 214 Small Molecule to Inhibit TDO-2 for Oncology 215 Small Molecule to Modulate Androgen Receptor for Muscle Disorders 216 Small Molecules to Activate CFTR for Cystic Fibrosis 217 Small Molecules to Inhibit Mps1 for Breast Cancer 218 Small Molecules to Inhibit NMT for Malaria 219 Small Molecules to Inhibit PDE2 for Osteoarthritis Pain 220 Vaccine 2 for Undisclosed Indication 221 Monoclonal Antibody Conjugates for Oncology 222 PF-00190434 223 PF-04445597 224 PF-46396 225 PPD-1 226 Small Molecule to Agonize LXR for Inflammation 227 Small Molecule to Agonize Melanocortin Receptor 3 for Rheumatoid Arthritis and Inflammation 228 Small Molecule to Antagonize Ghrelin Receptor for Alcoholism 229 Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing's Disease and Congenital Adrenal Hyperplasia 230 Small Molecule to Inhibit Acetyl-CoA Carboxylase for Metabolic Disorders 231 Small Molecule to Inhibit EZH2 for Oncology 232 Small Molecule to Inhibit MMP13 for Osteoarthritis 233 Small Molecule to Inhibit NS5A for HCV 234 Small Molecule to Inhibit PI3K Alpha and mTOR for Oncology 235 Small Molecule to Inhibit Pin1 for Oncology 236 Small Molecule to Target AGTR1 and PPAR gamma for Hypertension and Metabolic Syndrome 237 Small Molecules for Inflammatory and Orphan Diseases 238 Small Molecules for Obesity and Diabetes 239 Small Molecules for Ulcerative Colitis and Crohn's Disease 240 Small Molecules to Agonize A1 Adenosine Receptor 241 Small Molecules to Agonize ADRB2 and Antagonize CHRM3 for COPD 242 Pfizer Inc. - Pipeline Analysis 243 Pfizer Inc. - Pipeline Products by Target 243 Pfizer Inc. - Pipeline Products by Route of Administration 252 Pfizer Inc. - Pipeline Products by Molecule Type 253 Pfizer Inc. - Pipeline Products by Mechanism of Action 254 Pfizer Inc. - Recent Pipeline Updates 262 Pfizer Inc. - Dormant Projects 342 Pfizer Inc. - Discontinued Pipeline Products 349 Discontinued Pipeline Product Profiles 354 Pfizer Inc. - Company Statement 379 Pfizer Inc. - Locations And Subsidiaries 380 Head Office 380 Other Locations & Subsidiaries 380 Appendix 403 Methodology 403 Coverage 403 Secondary Research 403 Primary Research 403 Expert Panel Validation 403 Contact Us 403 Disclaimer 404
List of Tables Pfizer Inc., Key Information 23 Pfizer Inc., Key Facts 23 Pfizer Inc. - Pipeline by Indication, 2016 25 Pfizer Inc. - Pipeline by Stage of Development, 2016 36 Pfizer Inc. - Monotherapy Products in Pipeline, 2016 37 Pfizer Inc. - Combination Treatment Modalities in Pipeline, 2016 38 Pfizer Inc. - Partnered Products in Pipeline, 2016 39 Pfizer Inc. - Partnered Products/ Combination Treatment Modalities, 2016 40 Pfizer Inc. - Out-Licensed Products in Pipeline, 2016 42 Pfizer Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 43 Pfizer Inc. - Pre-Registration, 2016 46 Pfizer Inc. - Filing rejected/Withdrawn, 2016 47 Pfizer Inc. - Phase III, 2016 48 Pfizer Inc. - Phase II, 2016 50 Pfizer Inc. - Phase I, 2016 52 Pfizer Inc. - Preclinical, 2016 54 Pfizer Inc. - Discovery, 2016 56 Pfizer Inc. - Pipeline by Target, 2016 258 Pfizer Inc. - Pipeline by Route of Administration, 2016 267 Pfizer Inc. - Pipeline by Molecule Type, 2016 268 Pfizer Inc. - Pipeline Products by Mechanism of Action, 2016 269 Pfizer Inc. - Recent Pipeline Updates, 2016 277 Pfizer Inc. - Dormant Developmental Projects,2016 357 Pfizer Inc. - Discontinued Pipeline Products, 2016 364 Pfizer Inc., Other Locations 395 Pfizer Inc., Subsidiaries 395
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.